Viking Global Investors LP Karuna Therapeutics, Inc. Transaction History

Viking Global Investors LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $30.2 Million - $40 Million	183,308 Added 19.34%	1,131,263 $191 Million
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $97.5 Million - $133 Million	-553,119 Reduced 36.85%	947,955 $206 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $51.2 Million - $64.9 Million	317,338 Added 26.81%	1,501,074 $273 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $32.5 Million - $40.2 Million	169,620 Added 16.73%	1,183,736 $233 Million
Q3 2022 Nov 14, 2022	SELL	$123.79 - $277.42 $13 Million - $29.2 Million	-105,244 Reduced 9.4%	1,014,116 $228 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $13.6 Million - $20.8 Million	145,015 Added 14.88%	1,119,360 $142 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $10.9 Million - $14.7 Million	110,681 Added 12.82%	974,345 $124 Million
Q4 2021 Feb 14, 2022	SELL	$110.64 - $159.4 $556,740 - $802,100	-5,032 Reduced 0.58%	863,664 $113 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $4.68 Million - $5.82 Million	46,231 Added 5.62%	868,696 $106 Million
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $23.8 Million - $30.1 Million	221,321 Added 36.82%	822,465 $93.8 Million
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $25.1 Million - $35 Million	262,944 Added 77.75%	601,144 $72.3 Million
Q4 2020 Feb 16, 2021	SELL	$75.23 - $109.23 $24.5 Million - $35.6 Million	-325,690 Reduced 49.06%	338,200 $34.4 Million
Q3 2020 Nov 16, 2020	BUY	$71.31 - $109.74 $47.3 Million - $72.9 Million	663,890 New	663,890 $51.3 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.